 PALO ALTO, Calif., July 20, 2021 GLOBE NEWSWIRE -- Scilex Holding Company Scilex, a wholly-owned subsidiary of Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento, today announced complete enrollment of SP-102 SEMDEXATM Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica. SP-102 has received Fast Track status from the FDA. 